We are analyzing https://link.springer.com/article/10.1007/s11897-022-00539-0.

Title:
Mitochondria as Therapeutic Targets in Heart Failure | Current Heart Failure Reports
Description:
Purpose of Review We review therapeutic approaches aimed at restoring function of the failing heart by targeting mitochondrial reactive oxygen species (ROS), ion handling, and substrate utilization for adenosine triphosphate (ATP) production. Recent Findings Mitochondria-targeted therapies have been tested in animal models of and humans with heart failure (HF). Cardiac benefits of sodium/glucose cotransporter 2 inhibitors might be partly explained by their effects on ion handling and metabolism of cardiac myocytes. Summary The large energy requirements of the heart are met by oxidative phosphorylation in mitochondria, which is tightly regulated by the turnover of ATP that fuels cardiac contraction and relaxation. In heart failure (HF), this mechano-energetic coupling is disrupted, leading to bioenergetic mismatch and production of ROS that drive the progression of cardiac dysfunction. Furthermore, HF is accompanied by changes in substrate uptake and oxidation that are considered detrimental for mitochondrial oxidative metabolism and negatively affect cardiac efficiency. Mitochondria lie at the crossroads of metabolic and energetic dysfunction in HF and represent ideal therapeutic targets.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Fitness & Wellness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

pubmed, article, mitochondrial, google, scholar, cas, heart, cardiac, patients, failure, function, effects, elamipretide, central, sglti, trial, atp, metabolism, cardiovascular, oxidation, inhibition, fatty, oxidative, inhibitors, cytosolic, reduced, glucose, empagliflozin, targeting, production, treatment, diabetes, myocytes, matrix, mitochondria, hfref, results, mitoq, nhe, sglt, myocardial, failing, inhibiting, exchanger, clinical, acid, therapeutic, ros, dysfunction, trimetazidine,

Topics {✒️}

pressure-overload-induced heart failure article download pdf mitochondria-targeted cytoprotective peptides long-chain 3-ketoacyl coenzyme mitochondria-targeting cytoprotective peptide malonyl-coa decarboxylase inhibitors 36-week open-label extension reactive oxygen species mitochondria-targeting peptide bendavia digoxin accelerate ca2+ efflux malonyl-coa levels dictate targeting mitochondria-inflammation circuit sarcolemmal sodium-hydrogen exchanger mitochondria-targeted antioxidant mitoq empa-reg outcome trial microembolization-induced heart failure angiotensin ii-induced cardiomyopathy malonyl-coa decarboxylase provide manganese-dependent superoxide dismutase randomized dose-escalation trial pressure overload–induced hf sodium-hydrogen exchange inhibition fatty acid β-oxidation x-linked gene open access published increasing malonyl-coa levels extracellular na+-binding site myocardial ischemia/reperfusion injury mitochondrial na+/ca2+ exchanger sarcolemmal na+/ca2+ exchanger sarcolemmal na+/ca2+ exchanger late sodium current optimal medical therapy energy-starved failing heart high-risk ischemic situations mitochondrial-targeted peptides β-ohb oxidation requires l-type ca2+ channels directly inhibiting β-oxidation β-hydroxybutyrate mitigates hfpef late na+ current altered mechano-energetic coupling percutaneous coronary intervention lv end-systolic volume significant dose-dependent improvement krebs cycle-mediated regeneration mitochondria-targeting peptide elevated cytosolic sodium restoring mechano-energetic coupling general cellular—ros formation

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mitochondria as Therapeutic Targets in Heart Failure
         description:We review therapeutic approaches aimed at restoring function of the failing heart by targeting mitochondrial reactive oxygen species (ROS), ion handling, and substrate utilization for adenosine triphosphate (ATP) production. Mitochondria-targeted therapies have been tested in animal models of and humans with heart failure (HF). Cardiac benefits of sodium/glucose cotransporter 2 inhibitors might be partly explained by their effects on ion handling and metabolism of cardiac myocytes. The large energy requirements of the heart are met by oxidative phosphorylation in mitochondria, which is tightly regulated by the turnover of ATP that fuels cardiac contraction and relaxation. In heart failure (HF), this mechano-energetic coupling is disrupted, leading to bioenergetic mismatch and production of ROS that drive the progression of cardiac dysfunction. Furthermore, HF is accompanied by changes in substrate uptake and oxidation that are considered detrimental for mitochondrial oxidative metabolism and negatively affect cardiac efficiency. Mitochondria lie at the crossroads of metabolic and energetic dysfunction in HF and represent ideal therapeutic targets.
         datePublished:2022-02-11T00:00:00Z
         dateModified:2022-02-11T00:00:00Z
         pageStart:27
         pageEnd:37
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s11897-022-00539-0
         keywords:
            Mitochondria
            Heart failure
            Reactive oxygen species
            MitoQ
            Elamipretide
            SGLT2 inhibitors
            Cardiac metabolism
            Cardiology
            Cardiac Surgery
            Vascular Surgery
            Internal Medicine
            Imaging / Radiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11897-022-00539-0/MediaObjects/11897_2022_539_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11897-022-00539-0/MediaObjects/11897_2022_539_Fig2_HTML.png
         isPartOf:
            name:Current Heart Failure Reports
            issn:
               1546-9549
               1546-9530
            volumeNumber:19
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Julia Schwemmlein
               affiliation:
                     name:University Clinic Würzburg
                     address:
                        name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christoph Maack
               affiliation:
                     name:University Clinic Würzburg
                     address:
                        name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Edoardo Bertero
               affiliation:
                     name:University Clinic Würzburg
                     address:
                        name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
                        type:PostalAddress
                     type:Organization
                     name:University of Genoa
                     address:
                        name:Department of Internal Medicine and Specialties (Di.M.I.), University of Genoa, Genoa, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mitochondria as Therapeutic Targets in Heart Failure
      description:We review therapeutic approaches aimed at restoring function of the failing heart by targeting mitochondrial reactive oxygen species (ROS), ion handling, and substrate utilization for adenosine triphosphate (ATP) production. Mitochondria-targeted therapies have been tested in animal models of and humans with heart failure (HF). Cardiac benefits of sodium/glucose cotransporter 2 inhibitors might be partly explained by their effects on ion handling and metabolism of cardiac myocytes. The large energy requirements of the heart are met by oxidative phosphorylation in mitochondria, which is tightly regulated by the turnover of ATP that fuels cardiac contraction and relaxation. In heart failure (HF), this mechano-energetic coupling is disrupted, leading to bioenergetic mismatch and production of ROS that drive the progression of cardiac dysfunction. Furthermore, HF is accompanied by changes in substrate uptake and oxidation that are considered detrimental for mitochondrial oxidative metabolism and negatively affect cardiac efficiency. Mitochondria lie at the crossroads of metabolic and energetic dysfunction in HF and represent ideal therapeutic targets.
      datePublished:2022-02-11T00:00:00Z
      dateModified:2022-02-11T00:00:00Z
      pageStart:27
      pageEnd:37
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s11897-022-00539-0
      keywords:
         Mitochondria
         Heart failure
         Reactive oxygen species
         MitoQ
         Elamipretide
         SGLT2 inhibitors
         Cardiac metabolism
         Cardiology
         Cardiac Surgery
         Vascular Surgery
         Internal Medicine
         Imaging / Radiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11897-022-00539-0/MediaObjects/11897_2022_539_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11897-022-00539-0/MediaObjects/11897_2022_539_Fig2_HTML.png
      isPartOf:
         name:Current Heart Failure Reports
         issn:
            1546-9549
            1546-9530
         volumeNumber:19
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Julia Schwemmlein
            affiliation:
                  name:University Clinic Würzburg
                  address:
                     name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christoph Maack
            affiliation:
                  name:University Clinic Würzburg
                  address:
                     name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Edoardo Bertero
            affiliation:
                  name:University Clinic Würzburg
                  address:
                     name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
                     type:PostalAddress
                  type:Organization
                  name:University of Genoa
                  address:
                     name:Department of Internal Medicine and Specialties (Di.M.I.), University of Genoa, Genoa, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Current Heart Failure Reports
      issn:
         1546-9549
         1546-9530
      volumeNumber:19
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Clinic Würzburg
      address:
         name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
         type:PostalAddress
      name:University Clinic Würzburg
      address:
         name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
         type:PostalAddress
      name:University Clinic Würzburg
      address:
         name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
         type:PostalAddress
      name:University of Genoa
      address:
         name:Department of Internal Medicine and Specialties (Di.M.I.), University of Genoa, Genoa, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Julia Schwemmlein
      affiliation:
            name:University Clinic Würzburg
            address:
               name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
               type:PostalAddress
            type:Organization
      name:Christoph Maack
      affiliation:
            name:University Clinic Würzburg
            address:
               name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
               type:PostalAddress
            type:Organization
      name:Edoardo Bertero
      affiliation:
            name:University Clinic Würzburg
            address:
               name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
               type:PostalAddress
            type:Organization
            name:University of Genoa
            address:
               name:Department of Internal Medicine and Specialties (Di.M.I.), University of Genoa, Genoa, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
      name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
      name:Department of Translational Research, Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
      name:Department of Internal Medicine and Specialties (Di.M.I.), University of Genoa, Genoa, Italy

External Links {🔗}(338)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.78s.

LINK . SPRINGER . COM {}